Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy.


Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 03 05 2020
revised: 08 06 2020
accepted: 11 06 2020
pubmed: 8 8 2020
medline: 8 8 2020
entrez: 8 8 2020
Statut: ppublish

Résumé

Breast cancers show different regression patterns after neoadjuvant chemotherapy. Certain regression patterns are associated with more reliable margins in breast-conserving surgery. Our study aims to establish a nomogram based on radiomic features and clinicopathological factors to predict regression patterns in breast cancer patients. We retrospectively reviewed 144 breast cancer patients who received neoadjuvant chemotherapy and underwent definitive surgery in our center from January 2016 to December 2019. Tumor regression patterns were categorized as type 1 (concentric regression + pCR) and type 2 (multifocal residues + SD + PD) based on pathological results. We extracted 1158 multidimensional features from 2 sequences of MRI images. After feature selection, machine learning was applied to construct a radiomic signature. Clinical characteristics were selected by backward stepwise selection. The combined prediction model was built based on both the radiomic signature and clinical factors. The predictive performance of the combined prediction model was evaluated. Two radiomic features were selected for constructing the radiomic signature. Combined with two significant clinical characteristics, the combined prediction model showed excellent prediction performance, with an area under the receiver operating characteristic curve of 0.902 (95% confidence interval 0.8343-0.9701) in the primary cohort and 0.826 (95% confidence interval 0.6774-0.9753) in the validation cohort. Our study established a unique model combining a radiomic signature and clinicopathological factors to predict tumor regression patterns prior to the initiation of NAC. The early prediction of type 2 regression offers the opportunity to modify preoperative treatments or aids in determining surgical options.

Identifiants

pubmed: 32759037
pii: S1936-5233(20)30323-5
doi: 10.1016/j.tranon.2020.100831
pmc: PMC7399245
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100831

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Radiology. 2018 Jun;287(3):732-747
pubmed: 29782246
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2018 Jul 1;29(7):1497-1508
pubmed: 29873695
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Clin Cancer Res. 2017 Dec 1;23(23):7253-7262
pubmed: 28939744
World J Surg Oncol. 2013 Jul 24;11(1):166
pubmed: 23883300
Ann Oncol. 2012 Sep;23 Suppl 10:x231-6
pubmed: 22987968
Radiology. 2016 Mar;278(3):689-97
pubmed: 26418516
J Clin Oncol. 2006 Apr 20;24(12):1940-9
pubmed: 16622270
Cancer Manag Res. 2018 Oct 09;10:4333-4347
pubmed: 30349367
Neuroimage Clin. 2018 Apr 24;19:271-278
pubmed: 30035021
Clin Cancer Res. 2019 Jun 15;25(12):3538-3547
pubmed: 30842125
Breast Cancer. 2002;9(1):15-9
pubmed: 12196716
Radiology. 2018 Jan;286(1):49-57
pubmed: 28737968
Lancet Oncol. 2018 Jan;19(1):2-3
pubmed: 29242042
Ann Surg. 2010 Apr;251(4):701-7
pubmed: 20224378
Br J Surg. 2007 Oct;94(10):1189-200
pubmed: 17701939
Breast Cancer Res. 2018 Apr 18;20(1):34
pubmed: 29669584
J Clin Oncol. 2016 Jun 20;34(18):2157-64
pubmed: 27138577
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
Breast Cancer Res. 2017 Jul 10;19(1):80
pubmed: 28693537
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320
pubmed: 29523670
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
Breast Cancer Res Treat. 2017 Jul;164(2):285-294
pubmed: 28466123
Clin Transl Oncol. 2020 Jan;22(1):50-59
pubmed: 30977048
Breast J. 2017 Nov;23(6):656-662
pubmed: 28397346
J Clin Oncol. 2011 Feb 20;29(6):660-6
pubmed: 21220595
Ann Oncol. 2017 Oct 1;28(10):2420-2428
pubmed: 28961844
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):869-876
pubmed: 30885777

Auteurs

Xiaosheng Zhuang (X)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; Shantou University Medical College, Shantou 515041, Guangdong, China.

Chi Chen (C)

School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China; Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.

Zhenyu Liu (Z)

Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China; School of Artificial Intelligence, University of Chinese Academy of Science, Beijing 100080, China.

Liulu Zhang (L)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Xuezhi Zhou (X)

Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China; Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China.

Minyi Cheng (M)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Fei Ji (F)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Teng Zhu (T)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Chuqian Lei (C)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.

Junsheng Zhang (J)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; Shantou University Medical College, Shantou 515041, Guangdong, China.

Jingying Jiang (J)

Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing 100191, China; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing 100191, China. Electronic address: jingyingjiang@buaa.edu.cn.

Jie Tian (J)

Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China; School of Artificial Intelligence, University of Chinese Academy of Science, Beijing 100080, China; Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing 100191, China; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing 100191, China. Electronic address: jie.tian@ia.ac.cn.

Kun Wang (K)

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: gzwangkun@126.com.

Classifications MeSH